Mersana Therapeutics Inc (MRSN)

[jaybe]

Article in ADC Review notes Mersana's progress...

Pretty much a recap of JPM updates, potentially five abstracts at AACR in April:

1. Phase 1 data for XMT-1522, safety, efficacy, and RDP2.
2. Pre-clinical on XMT-1536 in IO combo.
3. Pre-clinical on next ADC, IND in 2018.
4. Pre-clinical on Takeda-ADC, IND in mid-2018.
5. Pre-clinical on new platform - new linker and PBD payload.

Likely at least 3 of the above, importantly #1 sets the table for all others. Abstracts posted online March 14.

https://adcreview.com/news/expanding-field-antibody-drug-conjugates/